Search results
Results from the WOW.Com Content Network
Most type 2 diabetes injections for weight loss are glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs mimic the GLP-1 hormone, which is made in your gastrointestinal tract when you ...
Peptide therapeutics are peptides or polypeptides (oligomers or short polymers of amino acids) which are used to for the treatment of diseases.Naturally occurring peptides may serve as hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives; peptide therapeutics mimic such functions.
The list price is the cost the drug manufacturer sets before applying insurance or discounts. ... Many medications fall into a class of drugs called GLP-1 (glucagon-like peptide-1) agonists ...
Native GLP-1 is a peptide hormone with a half-life of two minutes because it is rapidly cleared by the enzyme dipeptidyl peptidase-4. [27] As a result, different GLP-1 agonist drugs are modified in various ways to extend the half-life, resulting in drugs that can be dosed multiple times per day, daily, weekly, or less often. [27]
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. [6] [7] It is a second-line therapy for diabetes following first-line therapy with metformin.
Pramlintide has been approved on 3/16/2005 by the FDA, for use by type 1 and type 2 diabetic patients who use insulin. [6] (subscription required) Pramlintide allows patients to use less insulin, lowers average blood sugar levels, and substantially reduces what otherwise would be a large unhealthy rise in blood sugar that occurs in diabetics right after eating.
Aviptadil is an injectable synthetic formulation of human vasoactive intestinal peptide (VIP). [1] VIP was discovered in 1970, and has been used to treat various inflammatory conditions, such as acute respiratory distress syndrome (ARDS) , asthma , and chronic obstructive pulmonary disease (COPD) .
The medication is a peptide and acts by activating the melanocortin receptors. [1] [5] Bremelanotide was approved for medical use in the United States in 2019. [2] [6] It was developed by Palatin Technologies. [7] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [8]